EBOS Group posts rising revenue and EBITDA in HY26, keeps dividend steady

The EBOS Group Ltd (ASX: EBO) share price is in focus today after the company reported a 13% lift in revenue to $6.77 billion and a 3.2% increase in underlying EBITDA for the first half of FY26.

What did EBOS Group report?

• Revenue rose 13.0% to $6.77 billion (HY25: $5.99 billion)
• Underlying EBITDA increased 3.2% to $300 million
• Net Profit After Tax (statutory) up 13.0% to $125 million
• Interim dividend maintained at NZ 57.0 cents per share
• Leverage ratio of 2.2x, within target range
• Healthcare EBITDA up 1.3% to $254 million; Animal Care EBITDA up 15.1% to $68 million

What else do investors need to know?

EBOS’ Healthcare division delivered revenue growth, helped by continued customer wins, demand for high-value medicines, and expansion into medical technology and pharmacy networks. The major distribution centre renewal program is nearing completion, with six of eight new sites now operational—including its largest at Kemps Creek in Sydney, which is expected to generate further productivity gains.

Animal Care posted strong growth thanks to the successful acquisition and integration of vet wholesaler SVS and Next Generation Pet Foods, which contributed to a 48.3% jump in segment revenue. Retail Pharmacy Brands also expanded, with the acquisition of MediAdvice and digital engagement initiatives boosting network performance.

The company maintained a disciplined approach to capital management, successfully refinancing debt and keeping leverage within stated targets. The dividend reinvestment plan remains active, giving shareholders flexibility as the group wraps up its current capital investment cycle.

What did EBOS Group management say?

EBOS Group CEO, Adam Hall, said:

Our HY26 performance demonstrates the resilience and diversification of our portfolio as we continue to execute with discipline. We delivered strong revenue growth and reaffirmed our EBITDA guidance, supported by solid customer demand and the early benefits from our strategic investments. This sets us up well for H2 FY26, with additional opportunities from new stores and new products, as well as nearing the end of the current capital investment cycle.

What’s next for EBOS Group?

Looking ahead, management has reaffirmed FY26 EBITDA guidance and anticipates further improvement in the second half as productivity and utilisation continue to ramp up. The completion of the distribution centre program in FY26 is expected to improve efficiency and set up a multi-year growth runway, while capex is forecast to fall by around 30% in FY27, supporting stronger cash flows.

EBOS remains focused on its growth strategies for each division, including expanding distribution scale in healthcare, digital engagement in retail pharmacy, innovation in animal care, and medical technology expansion both in Australia/New Zealand and Southeast Asia.

EBOS Group share price snapshot

Over the past 12 months, EBOS Group shares have declined 42%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.

View Original Announcement

The post EBOS Group posts rising revenue and EBITDA in HY26, keeps dividend steady appeared first on The Motley Fool Australia.

More reading

• Fortescue delivers record shipments and a bigger dividend in H1 FY26 earnings
• Generation Development Group announces 63% jump in HY26 profit as FUM hits new record
• 3 ASX All Ords shares I’d buy with $5,000 today
• 5 things to watch on the ASX 200 on Wednesday
• Steadfast Group lifts revenue, profit, and dividend in 1H26 earnings update

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.